CoChat

12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study

Yamanaka, Takeharu, Oki, Eiji, Yamazaki, Kentaro, Yamaguchi, Kensei, Muro, Kei, Uetake, Hiroyuki, Sato, Takeo, Nishina, Tomohiro, Ikeda, Masataka, Kato, Takeshi, Kanazawa, Akiyoshi, Kusumoto, Tetsuya, Chao, Calvin, Lopatin, Margarita, Krishnakumar, Jayadevi, Bailey, Helen, Akagi, Kiwamu, Ochiai, Atsushi, Ohtsu, Atsushi, Ohashi, Yasuo, Yoshino, Takayuki · 2016 · Journal of Clinical Oncology
Cited by 76

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Purpose: The 12-gene Recurrence Score assay has been validated in resected stage II colon cancer treated with or without chemotherapy and resected stage III disease treated with chemotherapy. This study evaluated the 12-gene Recurrence Score assay for stage II and III colon cancer without chemotherapy to reveal the natural course of recurrence risk in stage III disease. Methods: A cohort-sampling design was used. From 1,487 consecutive patients with stage II to III disease who had surgery alone, 630 patients were sampled for inclusion with a 1:2 ratio of recurrence and nonrecurrence. Sampling was stratified by stage (II v III). The assay was performed on formalin-fixed, paraffin-embedded primary cancer tissue. Association of the Recurrence Score result with recurrence-free interval (RFI) was assessed by using weighted Cox proportional hazards regression. Results: Overall, 597 of 630 patients were analyzable—247 patients had stage II, and 350 had stage III colon cancer. The continuous Recurrence Score was significantly associated with RFI after adjustment for disease stage (hazard ratio for a 25-unit increase in Recurrence Score, 2.05; 95% CI, 1.47 to 2.86; P < .001). With respect to prespecified subgroups, as defined by low (< 30), intermediate (30 to 40), and high (≥ 41) Recurrence Score risk groups, patients with stage II disease in the high-risk group had a 5-year risk of recurrence similar to patients with stage IIIA to IIIB disease in the low-risk group (19% v 20%), whereas patients with stage IIIA to IIIB disease in the high-risk group had a recurrence risk similar to that of patients with stage IIIC disease in the low-risk group (approximately 38%). Conclusion: To our knowledge, this study provides the first validation of the 12-gene Recurrence Score assay in stage III colon cancer without chemotherapy and showed the heterogeneity of recurrence risks in stage III as well as in stage II colon cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.67.0414

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 76

Metadata

Authors
Yamanaka, T., Oki, E., Yamazaki, K., Yamaguchi, K., Muro, K., Uetake, H., Sato, T., Nishina, T., Ikeda, M., Kato, T., Kanazawa, A., Kusumoto, T., Chao, C., Lopatin, M., Krishnakumar, J., Bailey, H., Akagi, K., Ochiai, A., Ohtsu, A., Ohashi, Y., & Yoshino, T.
Venue
Journal of Clinical Oncology
Published
2016-08-20
Volume
34
Issue
24
Pages
2906-2913
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2473823649
Cited by
76
References
1
FWCI
3.71
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. https://app.cochat.ai/papers/10.1200/jco.2016.67.0414
The paper
Yamanaka, T., Oki, E., Yamazaki, K., Yamaguchi, K., Muro, K., Uetake, H., Sato, T., Nishina, T., Ikeda, M., Kato, T., Kanazawa, A., Kusumoto, T., Chao, C., Lopatin, M., Krishnakumar, J., Bailey, H., Akagi, K., Ochiai, A., Ohtsu, A., . . . Yoshino, T. (2016). 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.67.0414

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.